Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Feb. 6, 2025 (HealthDay News) — Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key driver mutations and induce antitumor immunity, according to a study published online Feb. 5 in Nature<\/em>.<\/p>\n David A. Braun, M.D., Ph.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted a phase 1 trial to examine a neoantigen-targeting PCV in nine patients with high-risk, fully resected clear cell RCC (stage\u2009III or IV), with or without ipilimumab administered adjacent to the vaccine.<\/p>\n The researchers found that none of the participants had a recurrence of RCC at a median follow-up of 40.2 months after surgery; there were no dose-limiting toxicities reported. T-cell immune responses against the PCV antigens were generated by all patients, including to RCC driver mutations in VHL<\/em>, PBRM1<\/em>, BAP1<\/em>, KDM5C<\/em>, and PIK3CA<\/em>. There was a durable expansion of peripheral T-cell clones observed following vaccination. In seven of nine patients, T-cell reactivity against autologous tumors was detected.<\/p>\n “The idea behind this trial was to specifically steer the immune system toward a target that is unique to the tumor,” Braun said in a statement. “For patients with high-risk clear cell RCC, we want to improve postsurgery treatment options that reduce the risk of the cancer coming back.”<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n